27-28 September, 2018

Boston, USA

Day One
Thursday, 27 September, 2018

Day Two
Friday, 28 September, 2018

Breakfast & Networking

Chair’s Opening Remarks

Overcoming Key Translational Challenges of Novel Pain Drug Development

Case Study:Pain in Mice and Man: Ironic Adventures in Translation

  • Jeffrey Mogil E.P. Taylor Professor of Pain Studies , McGill University


  • Translation of pain biology from preclinical to clinical has been challenging
  • Contributing reasons include issues surrounding genotype, sex, pain measurement, and
    clinical trials
  • Ironically, translation of social modulation of pain appears to be highly successful

Case Study:Promotion of Best Practices in Biomarker Discovery and Validation: A New Program at NINDS with an Emphasis on Pain Biomarkers


  • Why are biomarkers needed for the discovery of non-opioid pain therapeutics?
  • The process of biomarker discovery and validation
  • The new biomarker program at NINDS and its emphasis on non-opioid pain

Roundtable Discussion


Our breakout roundtables will allow you to have more intimate discussions with AI and pharma leaders around some of the hottest topics in the field. Discover multiple perspectives on these key issues, so that you can learn from your fellow experts in the audience. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself
in the following discussions:

The Effectiveness of Patient Selection and Patient-Reported Outcomes on the Success of Pain Clinical Trials

  • How to identify the right patient population for the right pain trial? What are the
    challenges and opportunities?
  • What are the considerations and challenges in selecting patient-reported outcome
    measures for pain clinical trials?

Networking & Morning Refreshments

Benchmarking Non-Opioid Pain Drugs in Clinical Development

Case Study:Mesenchymal Precursor Cells as a Non-Opioid Treatment for Low Back Pain


  • Single intra-discal injection
  • Durable pain reduction (up to 2 years)
  • Immunomodulation

Case Study:CC8464, Novel, Peripherally Restricted Pain Inhibitor Targeting Nav1.7


  • Strong evidence supporting the development of CC8464 for the treatment of
    neuropathic pain
  • Insights into potential efficacy beyond neuropathic pain
  • Update on clinical program

Adhesive Dermally Applied Microarray (ADAM) for the Treatment of Acute Migraine.


  • Adhesive Dermally Applied Microarray (ADAM) Delivery System provides:
    Rapid delivery and pulsatile PK profile for improved efficacy
    Room temperature stable formulations
    Patient friendly alternative to injection
  • In a recent clinical trial zolmitriptan ADAM delivery system was highly effective for the treatment of migraine, with statistical significance compared to placebo achieved for the two co-primary endpoints of pain freedom at 2 hours and most bothersome symptom absence at 2 hours
  • Easy to use and rapid zolmitriptan delivery for treatment of migraine may be a significant advantage

Case Study:Targeting Cannabinoid CB2 Receptors to Suppress Opioid Tolerance and Physical Dependence

  • Andrea Hohmann Linda and Jack Gill Chair of Neuroscience and Professor of Psychological and Brain Sciences , Indiana University


  • Targeting the endocannabinoid signalling system, including CB2 receptors, suppresses neuropathic pain without producing unwanted central nervous system side effects of direct acting CB1 agonists
  • Activation of cannabinoid CB2 receptors suppresses neuropathic pain without producing tolerance or withdrawal
  • A “failed” drug development clinical candidate, a G protein biased cannabinoid CB2 agonist, previously evaluated in a Phase 2 clinical trial for a different indication, suppresses chemotherapy-induced neuropathic pain, blocks development of opioid tolerance and attenuates signs of opioid withdrawal in rodents

Networking Lunch Followed by Chair’s Closing Remarks & Close of Inaugural Non-Opioid Pain Drug Development Summit 2018